Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 5:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 1,707 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Infusion Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effect of Sildenafil and Tadalafil on Skeletal Muscle and Perceptual Fatigue

NCT01661595
View directory record Official record
Conditions
Fatigue
Interventions
Sildenafil, tadalafil, Placebo
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
50 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Oct 19, 2026, 5:25 PM EDT
Completed Phase 1 Interventional

REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia

NCT04468971
View directory record Official record
Conditions
COVID19, ARDS
Interventions
CK0802, Placebo
Biological · Drug
Lead sponsor
Cellenkos, Inc.
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Baltimore, Maryland • New York, New York • Chapel Hill, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Oct 19, 2026, 5:25 PM EDT
Withdrawn Phase 4 Interventional

Exploring the Safety and Efficacy of Low-dose Ketamine Infusions for Pain Control in Acute Burn Injury

NCT03095222
View directory record Official record
Conditions
Pain
Interventions
Ketamine, Opioids
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2018 · Synced Oct 19, 2026, 5:25 PM EDT
Withdrawn Phase 2 Interventional

The Safety of a High-Dose, Rapid Infusion of Iron Sucrose

NCT02977611
View directory record Official record
Conditions
Iron Deficiency
Interventions
Iron sucrose
Drug
Lead sponsor
The Guthrie Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Sayre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 18, 2017 · Synced Oct 19, 2026, 5:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating the Safety and Pharmacokinetics of Ascending Single IV Doses of ERB-257

NCT00722501
View directory record Official record
Conditions
Healthy Subjects
Interventions
ERB-257, placebo
Drug · Other
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 28, 2009 · Synced Oct 19, 2026, 5:25 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Clinical Trial to Evaluate the Safety of Continuous IV Tirofiban in Acute Ischemic Stroke

NCT04818944
View directory record Official record
Conditions
Acute Ischemic Stroke, Ischemic Stroke
Interventions
Tirofiban Hydrochloride, Placebo
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Oct 19, 2026, 5:25 PM EDT
Not listed Phase 2Phase 3 Interventional Accepts healthy volunteers

Post-Operative Pain Control Using Direct Continuous Bupivacaine Infusion After Pelvic Organ Prolapse Repair

NCT00695240
View directory record Official record
Conditions
Post-Operative Pain, Pelvic Organ Prolapse
Interventions
Continuous bupivacaine analgesia infusion (ON-Q PainBuster Post-Op Pain Relief System)
Device
Lead sponsor
St. Luke's Hospital, Kansas City, Missouri
Other
Eligibility
18 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 11, 2008 · Synced Oct 19, 2026, 5:25 PM EDT
Completed Phase 4 Interventional

A Pilot Study of Continuous Subcutaneous Pramlintide Infusion Therapy in Patients With Type 1 Diabetes

NCT00502138
View directory record Official record
Conditions
IDDM
Interventions
Continuous Pramlintide infusion
Drug
Lead sponsor
University Diabetes & Endocrine Consultants
Other
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Oct 19, 2026, 5:25 PM EDT
Completed Phase 2 Interventional

Safety, Pharmacokinetics and Pharmacodynamics of BPS804 in Osteogenesis Imperfecta

NCT01417091
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
BPS804
Drug
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Anaheim, California • Miramar, Florida
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 19, 2026, 5:25 PM EDT
Completed Phase 4 Interventional Results available

A Study of Bonviva (Ibandronate) and Alendronate on Renal Function in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.

NCT00503113
View directory record Official record
Conditions
Post-Menopausal Osteoporosis
Interventions
ibandronate [Bonviva/Boniva], Alendronate
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
60 Years and older · Female only
Enrollment
801 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
15
States / cities
Birmingham, Alabama • Riverside, California • Lakewood, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2011 · Synced Oct 19, 2026, 5:25 PM EDT
Recruiting Phase 1 Interventional

Blood-Brain Barrier Disruption Using Exablate Magnetic Resonance-Guided Low Intensity Focused Ultrasound With Microbubbles in Combination With T-Cell Infusion in Patients With Newly Diagnosed Diffuse Midline Glioma (LIFT)

NCT07796061
View directory record Official record
Conditions
DMG, DIPG
Interventions
TAA-T Cell, BBB Disruption
Biological · Device
Lead sponsor
Children's National Research Institute
Other
Eligibility
3 Years to 25 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 19, 2026, 5:25 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion

NCT06158854
View directory record Official record
Conditions
Immunoglobulin Light Chain (AL) Amyloidosis
Interventions
ABBV-383 (Etentamig)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
12
States / cities
Miami, Florida • Boston, Massachusetts • Rochester, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 19, 2026, 5:25 PM EDT
Withdrawn Phase 4 Interventional

Effect of Surefire Infusion Device on Tumor Response to Regional Intra-arterial Therapy for Primary Liver Malignancies

NCT02853500
View directory record Official record
Conditions
Liver Cancer
Interventions
TriNav, Traditional Delivery, Doxorubicin
Device · Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Oct 19, 2026, 5:25 PM EDT
Terminated Not applicable Interventional

Fat Tolerance From Lipid Emulsion Infusion Packaged in Glass or Plastic

NCT00278928
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Liposyn III 20% (lipid infusion), Intralipid 20% (lipid infusion)
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
2 Days to 10 Days
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Oct 19, 2026, 5:25 PM EDT
Recruiting Not applicable Interventional

Prospective Randomized Observer Blinded Single Center Study Comparing 90-day Functional Outcome in Patients Who Received Intravenous Propofol Infusion Versus Inhalational Sevoflurane for General Anesthesia During Mechanical Thrombectomy in Patients Who Suffered From Acute Ischemic Stroke

NCT07001267
View directory record Official record
Conditions
Acute Ischemic Stroke Patients
Interventions
Anesthesia drugs during the surgery
Procedure
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 19, 2026, 5:25 PM EDT
Terminated Phase 1 Interventional

First in Human Trial of TAS266 in Patients With Advanced Solid Tumors

NCT01529307
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
TAS266
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
3
States / cities
Tampa, Florida • San Antonio, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Oct 19, 2026, 5:25 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Graft Versus Host Disease (GVHD)

NCT00366145
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
Prochymal®, Placebo, Standard of Care for GVHD
Biological · Drug
Lead sponsor
Mesoblast, Inc.
Industry
Eligibility
6 Months to 70 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
47
States / cities
Birmingham, Alabama • Tucson, Arizona • Duarte, California + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2022 · Synced Oct 19, 2026, 5:25 PM EDT
Completed Not applicable Interventional Results available

Mismatched Donor Lymphocyte Infusions for Relapsed Disease Following Allogeneic Stem Cell Transplantation

NCT00859586
View directory record Official record
Conditions
Leukemia, Myeloid, Acute, Leukemia, Lymphoblastic, Acute, Leukemia, Myelocytic, Chronic
Interventions
Miltenyi Magnetic cell sorter for CD3
Device
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
8 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 27, 2020 · Synced Oct 19, 2026, 5:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Metabolism and Excretion of [14C]-Rigosertib After Infusion to Volunteers

NCT02030639
View directory record Official record
Conditions
Healthy
Interventions
rigosertib
Drug
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 23, 2017 · Synced Oct 19, 2026, 5:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously

NCT00510029
View directory record Official record
Conditions
Arrhythmia
Interventions
GAP-134
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 13, 2008 · Synced Oct 19, 2026, 5:25 PM EDT
Completed Phase 2 Interventional Results available

Prevention of Post-Operative Nausea and Vomiting With Propofol Infusion

NCT05759481
View directory record Official record
Conditions
Post-operative Nausea and Vomiting
Interventions
Hybrid anesthesia (propofol + sevoflurane), Propofol only TIVA
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 19, 2026, 5:25 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Monitoring the Infusion Pressure in Insulin Infusion Sets in Healthy Adults

NCT02382536
View directory record Official record
Conditions
Diabetes
Interventions
BD Scarlett Infusion set, Medtronic QuickSet Infusion Set
Device
Lead sponsor
Becton, Dickinson and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Oct 19, 2026, 5:25 PM EDT
Completed Phase 1 Interventional

Expanded Natural Killer Cell Infusion in Treating Younger Patients With Recurrent/Refractory Brain Tumors

NCT02271711
View directory record Official record
Conditions
Recurrent Childhood Medulloblastoma, Recurrent Ependymoma, Recurrent Medulloblastoma
Interventions
Laboratory Biomarker Analysis, Natural Killer Cell Therapy
Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 21 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Oct 19, 2026, 5:25 PM EDT
Completed Phase 1 Interventional

A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Weekly x 4

NCT00002137
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Tecogalan sodium
Drug
Lead sponsor
Daiichi Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 19, 2026, 5:25 PM EDT